Details of the Drug

General Information of Drug (ID: DMHO0AR)

Drug Name
Ergocalciferol
Synonyms
Calciferol; Calciferolum; Condacaps; Condocaps; Condol; Crtron; Crystallina; Daral; Davitin; Decaps; Deltalin; Deratol; Detalup; Diactol; Drisdol; Ercalciol; Ergocalciferolo; Ergocalciferols; Ergocalciferolum; Ergorone; Ertron; Fortodyl; Geltabs; Haliver; Hyperkil; Infron; Metadee; Mulsiferol; Mykostin; Ostelin; Radiostol; Radstein; Radsterin; Rodinec; Sterogyl; Vigantol; Viostdrol; Viosterol; CALCIFEROL IN A GELATIN MATRIX; Component of Geltabs Vitamin D; Davitamon D; Divit urto; Ergocalciferolo [DCIT]; Ergosterol activated; Ergosterol irradiated; Geltabs Vitamin D; Irradiated ergosterol; Oleovitamin D; Rodine C; Synthetic Vitamin D; Viosterol in Oil; Calciferon 2; Mina D2; Oleovitamin D2; VITAMIN D2; VITAMIN_D2; Vitamina D2; Buco-D; Calciferol (TN); Calciferol (vitamin D2); D-Arthin; D-Tracetten; De-rat concentrate; Dee-Osterol; Dee-Ron; Dee-Ronal; Dee-Roual; Deltalin (TN); Drisdol (TN); Ergocalciferol (D2); Ergocalciferol: Vitamin D; Ergocalciferolum [INN-Latin]; Ergosterol, irradiated; Hi-Deratol; Novovitamin-D; Oleovitamin D, Synthetic; Shock-ferol; Shock-ferol sterogyl; Sorex C.R; Uvesterol-D; Vio-D; Vitamin d-2; Vitamin-D2; Vitavel-D; Ergocalciferol (JP15/USP); Ergocalciferol [INN:BAN:JAN]; Sorex C.R.; VITAMIN D2 WATER DISPERSABLE U.S.P.; CALCIFEROL, U.S.P.; Irradiated ergosta-5,7,22-trien-3-beta-ol; Irradiated ergosta-5,7,22-trien-3.beta.-ol; (+)-Vitamin D2; (3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol; (3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; 7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87; 9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol;9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
Indication
Disease Entry ICD 11 Status REF
Hypoparathyroidism 5A50 Approved [1]
Osteoporosis FB83.0 Approved [2]
Pleural tuberculosis N.A. Approved [2]
Rickets 5B57 Approved [2]
Vitamin D deficiency 5B57 Approved [2]
Vitamin D-dependent rickets N.A. Approved [2]
Vitamin deficiency 5B55-5B71 Approved [2]
Autosomal dominant hypocalcemia 5A50.0Y Investigative [2]
X-linked dominant hypophosphatemic rickets N.A. Investigative [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Vitamins
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 396.6
Logarithm of the Partition Coefficient (xlogp) 7.4
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The renal clearance of drug is 31 mL/min []
Half-life
The concentration or amount of drug in body reduced by one-half in 1 - 2 days [4]
Metabolism
The drug is metabolized via the conversion of this parent compound to 25-hydroxyvitamin D by the action of CYP2R1 []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.86436 micromolar/kg/day [5]
Chemical Identifiers
Formula
C28H44O
IUPAC Name
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
Canonical SMILES
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
InChI
InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
InChIKey
MECHNRXZTMCUDQ-RKHKHRCZSA-N
Cross-matching ID
PubChem CID
5280793
ChEBI ID
CHEBI:28934
CAS Number
50-14-6
DrugBank ID
DB00153
TTD ID
D06JPB
INTEDE ID
DR0596
ACDINA ID
D00237
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin D3 receptor (VDR) TTK59TV VDR_HUMAN Antagonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [7]
Cholesterol desmolase (CYP11A1) DE98XPV CP11A_HUMAN Substrate [8]
Cytochrome P450 2J2 (CYP2J2) DERSX5P CP2J2_HUMAN Substrate [9]
Vitamin D 25-hydroxylase (CYP2R1) DEBIHM3 CP2R1_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) OTHCDQ22 PRGC1_HUMAN Gene/Protein Processing [11]
Thyroxine 5-deiodinase (DIO3) OTNTITOT IOD3_HUMAN Gene/Protein Processing [12]
Type I iodothyronine deiodinase (DIO1) OTFYLYJ0 IOD1_HUMAN Gene/Protein Processing [12]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Gene/Protein Processing [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypoparathyroidism
ICD Disease Classification 5A50
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vitamin D3 receptor (VDR) DTT VDR 1.80E-03 -0.18 -0.42
Cytochrome P450 2J2 (CYP2J2) DME CYP2J2 3.14E-01 2.37E-02 8.44E-02
Vitamin D 25-hydroxylase (CYP2R1) DME CYP2R1 6.11E-08 9.96E-02 4.58E-01
Cholesterol desmolase (CYP11A1) DME CYP11A1 2.07E-01 2.50E-02 1.32E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 7.29E-03 -3.47E-02 -1.80E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ergocalciferol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Magnesium Sulfate DMVEK07 Moderate Increased risk of hypermagnesemia by the combination of Ergocalciferol and Magnesium Sulfate. Acute pain [MG31] [13]
Butalbital DM9J04X Moderate Increased metabolism of Ergocalciferol caused by Butalbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [13]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Ergocalciferol caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [13]
Secobarbital DM14RF5 Moderate Increased metabolism of Ergocalciferol caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [13]
Primidone DM0WX6I Moderate Increased metabolism of Ergocalciferol caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Felbamate DM1V5ZS Moderate Increased metabolism of Ergocalciferol caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Ergocalciferol caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Phenytoin DMNOKBV Moderate Increased metabolism of Ergocalciferol caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Ergocalciferol caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Rufinamide DMWE60C Moderate Increased metabolism of Ergocalciferol caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Phenobarbital DMXZOCG Moderate Increased metabolism of Ergocalciferol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Carbamazepine DMZOLBI Moderate Increased metabolism of Ergocalciferol caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Cimetidine DMH61ZB Minor Decreased metabolism of Ergocalciferol caused by Cimetidine mediated inhibition of non-CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [14]
Isoniazid DM5JVS3 Moderate Increased metabolism of Ergocalciferol caused by Isoniazid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [13]
Rifampin DMA8J1G Moderate Increased metabolism of Ergocalciferol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [13]
Rifapentine DMCHV4I Moderate Increased metabolism of Ergocalciferol caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [13]
Amobarbital DM0GQ8N Moderate Increased metabolism of Ergocalciferol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [13]
Butabarbital DMC5AST Moderate Increased metabolism of Ergocalciferol caused by Butabarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [13]
Pentobarbital DMFNH7L Moderate Increased metabolism of Ergocalciferol caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [13]
Rifabutin DM1YBHK Moderate Increased metabolism of Ergocalciferol caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [13]
Orlistat DMRJSP8 Minor Decreased absorption of Ergocalciferol caused by Orlistat. Obesity [5B80-5B81] [15]
⏷ Show the Full List of 21 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Butylparaben E00142 7184 Antimicrobial preservative
FD&C blue no. 1 E00263 19700 Colorant
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Ethylene glycol ethyl ether E00164 8076 Solubilizing agent; Solvent
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Soybean lecithin E00637 Not Available Other agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ergocalciferol 50000 unt capsule 50000 unt Oral Capsule Oral
Ergocalciferol 1.25 mg capsule 1.25 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040833.
2 Ergocalciferol FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
7 CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res. 2004 Apr;19(4):680-8.
8 Vitamin D: mechanisms of action and clinical applications. Endocrinol Metab Clin North Am. 2017 Dec;46(4):xvii-xviii.
9 Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
10 CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev. 2007 Nov;23(8):631-6.
11 A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.
12 Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases. Toxicol Sci. 2019 Apr 1;168(2):430-442. doi: 10.1093/toxsci/kfy302.
13 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
14 Odes HS, Fraser GM, Krugliak P, et al "Effect of cimetidine on hepatic vitamin D metabolism in humans." Digestion 46 (1990): 61-4. [PMID: 2253823]
15 Product Information. Xenical (orlistat). Roche Laboratories, Nutley, NJ.